OncoCyte EPS - Earnings per Share 2014-2025 | IMDX
OncoCyte eps - earnings per share from 2014 to 2025. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| OncoCyte Annual EPS |
| 2024 |
$-4.66 |
| 2023 |
$-3.75 |
| 2022 |
$-13.25 |
| 2021 |
$-14.40 |
| 2020 |
$-9.20 |
| 2019 |
$-8.80 |
| 2018 |
$-8.40 |
| 2017 |
$-12.80 |
| 2016 |
$-8.40 |
| 2015 |
$-8.40 |
| 2014 |
$-5.40 |
| 2013 |
$-3.80 |
| OncoCyte Quarterly EPS |
| 2025-03-31 |
$-0.26 |
| 2024-12-31 |
$-2.19 |
| 2024-09-30 |
$-0.98 |
| 2024-06-30 |
$-0.36 |
| 2024-03-31 |
$-1.13 |
| 2023-12-31 |
$-2.27 |
| 2023-09-30 |
$-0.81 |
| 2023-06-30 |
$-1.07 |
| 2023-03-31 |
$0.40 |
| 2022-12-31 |
$-7.95 |
| 2022-09-30 |
$-1.62 |
| 2022-06-30 |
$-1.48 |
| 2022-03-31 |
$-2.20 |
| 2021-12-31 |
$-8.00 |
| 2021-09-30 |
$-3.00 |
| 2021-06-30 |
$-2.40 |
| 2021-03-31 |
$-1.00 |
| 2020-12-31 |
$-1.80 |
| 2020-09-30 |
$-2.00 |
| 2020-06-30 |
$-2.80 |
| 2020-03-31 |
$-2.60 |
| 2019-12-31 |
$-3.20 |
| 2019-09-30 |
$-2.00 |
| 2019-06-30 |
$-2.00 |
| 2019-03-31 |
$-1.60 |
| 2018-12-31 |
$-2.20 |
| 2018-09-30 |
$-1.40 |
| 2018-06-30 |
$-2.40 |
| 2018-03-31 |
$-2.40 |
| 2017-12-31 |
$-2.60 |
| 2017-09-30 |
$-4.40 |
| 2017-06-30 |
$-2.60 |
| 2017-03-31 |
$-3.20 |
| 2016-12-31 |
$-2.00 |
| 2016-09-30 |
$-2.00 |
| 2016-06-30 |
$-2.00 |
| 2016-03-31 |
$-2.40 |
| 2015-12-31 |
$-2.80 |
| 2015-09-30 |
$-2.40 |
| 2015-06-30 |
$-1.40 |
| 2015-03-31 |
$-1.60 |
| 2014-12-31 |
$0.00 |
| 2013-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$0.090B |
$0.002B |
|
OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.
|
